This protocol addresses patients with a peptic stricture located in the distal third of the esophagus in the setting of gastroesophageal reflux disease (GERD). GERD-driven chronic inflammation, ulceration, and fibrosis of the distal esophagus underlies the development of these peptic strictures; their presence is itself conclusive evidence of GERD.
Initial management with endoscopic balloon or bougie dilation combined with indefinite acid suppressive therapy was the first-line approach. When the stricture and dysphagia have not resolved — typically defined as requiring more than the expected number of dilation sessions — the stricture is considered refractory and this next-step protocol applies.
Gastroesophageal reflux disease (GERD) can cause inflammation, ulceration, and fibrosis of the distal esophagus, leading to the development of peptic strictures. Peptic strictures are conclusive evidence for a diagnosis of GERD.
For refractory peptic strictures, triamcinolone injection into the stricture prior to dilation or stent placement can reduce the risk of stricture recurrence. In a controlled trial of 30 patients with a recurrent peptic esophageal stricture, patients were randomized to receive either steroid injection (40 mg triamcinolone injected in four 1 mL aliquots of saline solution) or sham injection into the stricture followed by balloon dilation of the stricture.
DOI: 10.1016/j.giec.2025.02.002
View source ↗